India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Florida’s insurance market is under intense pressure as millions of residents and trillions in property wealth cluster along hurricane‑vulnerable coastlines. This article breaks down how decades of growth in high‑risk zones created today’s crisis, why traditional pricing models can’t keep up, and what real estate and insurance professionals must do to stay ahead. It offers actionable insights on underwriting, risk communication, policy partnerships, and resilience planning—critical knowledge for anyone advising Florida homeowners or navigating the state’s evolving insurance landscape.
Florida’s homeowners insurance market may have stabilized, but not in the way residents hoped. After years of runaway increases, premiums have stopped spiking—but they’re holding at painfully high levels. Coastal properties remain the hardest hit, with some policies topping $15,000 a year, while insurers continue demanding costly upgrades and resisting calls for transparency. For real estate professionals, understanding these pricing pressures is becoming essential as insurance costs increasingly shape buyer decisions across the state.
Florida homeowners face soaring premiums, shrinking insurer options, and storms that grow stronger each year. This article breaks down what hurricane insurance actually covers, how deductibles really work, why flood insurance is essential, and what professionals in real estate, mortgage, and insurance must understand to protect clients and properties before the next major storm hits.
Teresa King Kinney, one of the most influential executives in modern real estate, is retiring after 33 years as CEO of the MIAMI Association of Realtors. Under her leadership, the organization grew from 5,000 members to 60,000, became a global real estate powerhouse, and built the nation’s largest association‑owned MLS. As she transitions into CEO Emeritus, MIAMI prepares for a new era shaped by the foundation she spent decades building.
Miami’s commercial property market is heating up again, posting an 11% jump in investment volume for 2025. The surge is driven largely by a revitalized retail sector fueled by population growth, strong tourism, and new mixed‑use development. While office and industrial activity remains steady but softer, investor confidence is returning as Miami’s CRE landscape matures and buyers re‑enter the market with renewed interest in high‑traffic retail opportunities.
The Federal Reserve is preparing major changes to mortgage regulations in an effort to pull more mortgage activity back into the banking sector. With banks losing significant market share to nonbank lenders over the past decade, Fed Vice Chair for Supervision Michelle Bowman says new proposals may ease capital requirements and make mortgage servicing more attractive for banks. These shifts could have wide‑ranging effects on real estate professionals, lenders, and borrowers as the balance of power in the mortgage market begins to shift once again.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
